tbuckley/cabot-search huggingface dataset:
Opioid Prescribing Trends and the Physician’s Role in Responding to the Public Health Crisis
Authors: Jerome M. Adams, Brett P. Giroir
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML
Authors: Jessica Barth, Khalil Abou-El-Ardat, Denis Dalic, Nina Kurrle, Anna-Maria Maier, Sebastian Mohr, Judith Schütte, Lothar Vassen, Gabriele Greve, Johannes Schulz-Fincke, Martin Schmitt, Milica Tosic, Eric Metzger, Gesine Bug, Cyrus Khandanpour, Sebastian A. Wagner, Michael Lübbert, Manfred Jung, Hubert Serve, Roland Schüle, Tobias Berg
Journal: Leukemia (2019)
Self-sacrifice for in-group's history: A diachronic perspective
Authors: Maria Babińska, Michal Bilewicz
Journal: Behavioral and Brain Sciences (2018)

Abstract The problem of extended fusion and identification can be approached from a diachronic perspective. Based on our own research, as well as findings from the fields of social, political, and clinical psychology, we argue that the way contemporary emotional events shape local fusion is similar to the way in which historical experiences shape extended fusion. We propose a reciprocal process in which historical events shape contemporary identities, whereas contemporary identities shape interpretations of past traumas.
Comparison of FLT3-ITD Detection By High-Throughput Amplicon Sequencing to Routine Diagnostics - a Retrospective Analysis of AMLCG Study Patients
Authors: Katrin Reiter, Max Hubmann, Egor Harin, Sebastian Vosberg, Kathrin Bräundl, Bianka Ksienzyk, Stephanie Schneider, Annika Maria Dufour, Evelyn Zellmeier, Stefan K. Bohlander, Christina Sauerland, Wolfgang E Berdel, Bernhard J Wörmann, Thomas Büchner, Jan Braess, Wolfgang Hiddemann, Karsten Spiekermann, Philipp A. Greif
Journal: Blood (2016)
Genomic Analysis of Ibrutinib Resistance in Waldenstrom Macroglobulinemia
Authors: Cristina Jimenez, Gloria G Chan, Lian Xu, Nickolas Tsakmaklis, Jiaji G Chen, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, Xia Liu, Manit Munshi, Joshua Gustine, Guang Yang, Jorge J. Castillo, Steven P Treon, Zachary R Hunter
Journal: Blood (2018)
Abstract 11967: Soluble St2 is Regulated By P75NTR and Predicts Mortality in Diabetic Patients With Critical Limb Ischemia
Authors: Andrea Caporali, Marco Meloni, Ashely M Miller, Klemens Vierlinger, Christa Noehammer Noehammer, Gaia Spinetti, Orazio Fortunato, Paolo Madeddu, Costanza Emanueli
Journal: Circulation (2012)

BACKGROUND: The neurotrophin p75NTR receptor contributes into diabetes mellitus (DM)-induced defective post-ischemic neovascularization. The interleukin-33 receptor ST2 (also known as IL-1RL1) is e...
Clinicopathological features, efficacy of anti-EGFR therapy, and survival outcomes in patients with <i>BRAF</i> non-V600 mutated metastatic colorectal cancer.
Authors: Daisuke Kotani, Sebastián Mondaca, Aparna Parikh, Hideaki Bando, Emily Van Seventer, Hiroya Taniguchi, Takayuki Yoshino, Ryan Bruce Corcoran, Rona Yaeger, Hiromichi Ebi
Journal: Journal of Clinical Oncology (2019)

659 Background: BRAF non-V600 mutations occur in 2-3% of colorectal cancer. These mutants can be classified as RAS independent (class 2) or RAS dependent (class 3). We reported BRAF non-V600 mutations could be a negative predictive factor for anti-EGFR therapy in patients (pts) with pretreated metastatic colorectal cancer (mCRC), while mCRC pts with class 3 BRAF mutations could respond to anti-EGFR therapy because of its dependency on receptors and RAS. Methods: This study evaluates the efficacy to anti-EGFR therapy in a large cohort of pts with BRAF non-V600 mutated mCRC. Pts with mCRC referred to the participating centers from 2010 to 2017 were included. Clinicopathological features, efficacy of anti-EGFR therapy, and survival outcomes were stratified by BRAF mutational class. Results: One hundred seventeen pts with BRAF non-V600 mutated mCRC were identified. Median age was 58 years (range, 27-83), 68 pts (58%) were male, and 38 pts (33%) had right-sided tumors. Mucinous histology was seen in 11 cases (9%); concurrent RAS mutations occurred in 31 cases (27%), and 3 cases (3%) were MSI-H. Also, TP53 mutations were detected in 74 pts among 90 analyzed cases (82%). Regarding BRAF mutation subtype, 25/63/29 pts were classified as class 2/3/not reported (NR), respectively. Median OS in RAS wild-type/mutant were 44.8/34.6 months, respectively (p=0.082). The median OS in RAS wild-type pts with BRAF non-V600 mutations for class 2, 3, and NR were 25.7, 44.2, and 79.1 months, respectively (class 2 vs. 3, p=0.219). Among 40 pts treated with anti-EGFR therapy, response rates were 14%, 44%, and 40% for class 2, 3, and NR, respectively. Median PFS was 4.4, 8.3, 4.0 months for class 2, 3, and NR, respectively. Moreover, in 25 pts receiving anti-EGFR therapy as third or later line, response rate was 0%, 27%, and 50% in class 2, 3, and NR, and median PFS was 2.8, 3.7, and 4.0 months (p=0.762), respectively. Conclusions: Pts with class 2 BRAF mutations tend to have a poor prognosis compared to those with class 3 mutations. While almost half of pts with class 3 BRAF mutations responded to anti-EGFR therapy, response was rare for pts with class 2 BRAF mutations, and none achieved objective response in the third or later line.
Rosiglitazone improves myocardial glucose uptake in ischemic regions in patients with type 2 diabetes. A 16 week randomised, double-blind, placebo-controlled study
Authors: R Lautamaki, Kej Airaksinen, M Seppanen, J Toikka, M Luotolahti, E Ball, R Borra, R Harkonen, J Knuuti, M Stewart, P Nuutila
Journal: Journal of the American College of Cardiology (2005)
Abstract 13081: Large Volume Intra-Aortic Balloon Counterpulsation: Efficacy and Safety of the <i>Mega 50cc</i> in 150 Consecutive Patients
Authors: Gautam K Visveswaran, Marc Cohen, Michael Divita, Ahmed Seliem, Amar Dave, Jonathan E Swinden, Najam Wasty, David A Baran
Journal: Circulation (2015)

Background: Intraaortic balloon counterpulsation (IABC) with the larger volume (LV) 50 cc Mega balloon offers greater aortic diastolic augmentation and systolic unloading than its 40cc predecessor. We retrospectively analyzed our single center tertiary care experience with 150 consecutive patients (pts) with LV IABC to gauge its efficacy and safety. Methods: Retrospective chart review for demographic, procedural, safety and in-hospital outcome data was undertaken on 150 pts. In 64 pts, hemodynamic data by Swan was available pre- IABC, and 4, 24, and 48 hours during IABC. Results: LV IABC was deployed for cardiogenic shock and/or CHF (n=128), coronary ischemia (n=11), or high risk PCI/surgery (n=11): Mean age 58±15 with 18% over age 80, 21% female, 36% % African-American. The median LVEF was 22% (15.3%-33.2%) and 37% were non-ischemic myopathy. 19% of IABC insertions were emergent at bedside without fluoroscopy. Median duration of IABC was 92 hrs (48hrs-235 hrs) during which a leak or poor augmentation developed in 3%. 3(2%) pts had major vascular complications; 3(2%) pts had major bleeding. 51(34%) pts escalated from IABC to Impella, LVAD, or heart transplantation. Overall, in-hospital mortality was 27%. In the subgroup of 100 pts in whom IABC was the initial therapy for cardiogenic shock mortality was only 32%. Hemodynamic data (64 pts) pre-IABC vs 48 hrs: Aortic systolic pressure decreased (mean systolic unloading) -10.7 +/-25 mmHg; absolute Aortic diastolic pressure (augmented dias AoP) 108 ± 22mmHg; mean PA decreased -5.4±11; mean RA -3.2±6 (all p &lt;0.05). Cardiac output and index increased by of 0.7±1.6 l/min, and 0.4±0.8 l/min/m2 respectively (p&lt;0.005). Conclusion: LV IABC with the 50cc Mega balloon is a safe first line percutaneous support strategy in critically ill pts with easy bed-side deployment and relatively few device related complications. Despite conflicting results from clinical trials, we observed, a significant improvement in hemodynamic indices in a broad range of pts with relatively few vascular and bleeding complications with IABC. Among the 100 pts in whom IABC was the initial ventricular assist therapy for cardiogenic shock, survival to hospital discharge was 68%.
A T-cell–engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer
Authors: Akira Iizuka, Chizu Nonomura, Tadashi Ashizawa, Ryota Kondou, Keiichi Ohshima, Takashi Sugino, Koichi Mitsuya, Nakamasa Hayashi, Yoko Nakasu, Kouji Maruyama, Ken Yamaguchi, Yasuto Akiyama
Journal: Clinical Cancer Research (2019)

Abstract Purpose: The B7 homolog 4 (B7-H4, VTCN1) is an immune checkpoint molecule that negatively regulates immune responses and is known to be overexpressed in many human cancers. Previously, we generated a mouse anti-human B7-H4 mAb that did not have a significant antitumor effect in vivo probably because of molecule instability. In this study, we designed a B7-H4/CD3-bispecific antibody (BsAb) and investigated its antitumor activity in vitro and in vivo using a humanized mouse model. Experimental Design: cDNAs of the antibody-binding fragment (Fab)–single-chain variable fragment (scFv) and scFv-scFv of the anti-B7-H4/CD3 BsAb were synthesized, and the BsAb antibodies were produced in HEK293 cells. The antitumor activity against human breast cancer cells by human peripheral blood mononuclear cells (hPBMC) with BsAb was measured by lactate dehydrogenase release in vitro, and in vivo using hPBMC-transplanted MHC class I- and class II–deficient NOG mice. Results: hPBMCs with anti-B7-H4/CD3 BsAbs successfully lysed the human breast cancer cell line MDA-MB-468 (EC50: 0.2 ng/mL) and other B7-H4+ cell lines in vitro. When BsAb was injected in a humanized mouse model, there was an immediate and strong antitumor activity against MDA-MB-468, HCC-1954, and HCC-1569 tumors and CD8+ and granzyme B+ CTL infiltration into the tumor, and there were no adverse effects after long-term observation. CD8+ T-cell depletion by an anti-CD8 antibody mostly reduced the antitumor effect of BsAb in vivo. Conclusions: An anti-B7-H4/CD3 BsAb may be a good therapeutic tool for patients with B7-H4+ breast cancers.
Determining Best Tests of Baked Egg Tolerance in Egg Allergic Subjects
Authors: Ursula R. Janikowski, Ashley L. Devonshire, Kathryn M. Barbon, Opal Gupta, Maaria Syed, Mendy Miller, Miao Cai, Melanie M. Makhija, Anne Marie Singh
Journal: Journal of Allergy and Clinical Immunology (2019)
The Combination of Complex Karyotypes' Subtypes and IGHV Mutational Status Provides Prognostic and Predictive Information in Chronic Lymphocytic Leukemia
Authors: Andrea Visentin, Laura Bonaldi, Gian Matteo Rigolin, Francesca Romana Mauro, Annalisa Martines, Federica Frezzato, Silvia Imbergamo, Edoardo Scomazzon, Stefano Pravato, Antonella Bardi, Maurizio Cavallari, Eleonora Volta, Francesco Cavazzini, Mauro Nanni, Ilaria Del Giudice, Monica Facco, Anna Guarini, Robin Foà, Gianpietro Semenzato, Antonio Cuneo, Livio Trentin
Journal: Blood (2018)
Oral tolerance versus immunological mechanism in children with cow’s milk allergy
Authors: Luiza M. Marino, Ana C. Rozalem-Reali, Barbara Luiza B Cancado, Julio Cesar Gontijo, Renan Augusto Pereira, Isabella B. Manhaes, Marilia M. Moraes, Carolina S. Aranda, Renata R. Cocco, Marcia C. Mallozi, Dirceu Sole
Journal: Journal of Allergy and Clinical Immunology (2019)
Impact of Treatment Free Remission (TFR) with Nilotinib in 2nd Line for Chronic Myeloid Leukemia on Savings That May Fund All BCR-ABL Tests in the Brazilian Public Healthcare System during and after Nilotinib Treatment
Authors: Andre Abdo, Carla Maria Boquimpani, Douglas Vivona, Viviane Silveira Leite, Alisson L. Matsuo, Vanessa Teich, Israel Bendit, Eduardo Magalhães Rego, Vanderson Rocha
Journal: Blood (2018)
Improving Treatment Related Mortality over Time - Data from the Non-Observational Trial on Autologous Stem Cell Transplantation in Systemic Sclerosis By the EBMT Autoimmune Diseases Working Party (ADWP)
Authors: Dominique Farge, John A Snowden, Manuela Badoglio, Myriam Labopin, Hans Ulrich Scherer, Nicoletta Del Papa, Lothar Kanz, Marc Schmalzing, Thierry Martin, Montserrat Rovira, Thomas Daikeler, Gregory Pugnet, Joerg Henes
Journal: Blood (2018)
Abstract P308: Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease
Authors: George Thanassoulis, Ken Williams, Kathleen K Altobelli, Michael J Pencina, Christopher P Cannon, Allan D Sniderman, Allan D Sniderman
Journal: Circulation (2016)

Background: Current guidelines recommend statins in primary prevention of cardiovascular disease based on predicted cardiovascular risk without directly considering the expected benefits of statin therapy based on the available randomized trial (RCT) evidence. Methods and Results: We included 2,134 participants representing 71.8 million American residents potentially eligible for statins in primary prevention from the National Health and Nutrition Examination Survey for years 2005 - 2010. We compared statin eligibilities using three separate approaches: a 10-year risk-based approach, a trials-based approach (i.e. based on inclusion criteria of statin RCTs) and an individualized benefit approach (i.e. based on a predicted absolute risk reduction over 10 years [ARR 10 ] ≥2.5% using RCT data). A risk-based, a trials-based approach or a benefit-based approach led to the eligibility of (in millions of Americans): 15.0 (95% confidence interval 13.3-16.8), 24.7 (22.4-27.0) and 24.0 (21.2-26.7), respectively. The corresponding number needed to treat over 10 years was 19 (range: 9-40), 33 (9-1000) and 23 (9-40). A benefit-based approach identified 8.9 million lower-risk (&lt;7.5% 10 year risk) Americans, not currently eligible for statin treatment, who had the same or greater expected benefit from statins (≥2.5% ARR 10 ) as higher-risk individuals. This lower-risk/acceptable-benefit group includes younger individuals (mean age 55.3 years vs. 62.5 years;p&lt;0.001 for benefit-based vs risk-based) with higher LDL-C (140 mg/dL vs. 133 mg/dL; p=0.01). Conclusions: An individualized statin benefit approach can identify lower-risk individuals who have equal or greater expected benefit from statins in primary prevention than higher-risk individuals. This may help identify individuals who would meaningfully benefit from earlier initiation of statin therapy.
Response by Sheikh et al to Letter Regarding Article, “Diagnostic Yield of Genetic Testing in Young Athletes With T-Wave Inversion”
Authors: Nabeel Sheikh, Michael Papadakis, Mathew Wilson, Aneil Malhotra, Carmen Adamuz, Tessa Homfray, Lorenzo Monserrat, Elijah R. Behr, Sanjay Sharma
Journal: Circulation (2019)
Burkitt Lymphoma in Adolescents and Adults in Malawi: A Prospective Cohort Study
Authors: Matthew Painschab, Kate Westmoreland, Edwards Kasonkanji, Takondwa Zuze, Bongani Kaimila, Tamiwe Tomoka, Maurice Mulenga, Nathan D Montgomery, Yuri Fedoriw, Satish Gopal
Journal: Blood (2018)
Increased Disease Burden Among Black Children Compared to White Children with Newly Diagnosed Acute Myeloid Leukemia
Authors: Lena E. Winestone, Kelly D Getz, Yimei Li, Evanette Burrows, Michael Scheurer, M. Monica Gramatges, Jennifer J. Wilkes, Tamara P. Miller, Alix E. Seif, Robert W. Grundmeier, Karen R. Rabin, Brian T. Fisher, Richard Aplenc
Journal: Blood (2018)
The role of (bounded) optimization in theory testing and prediction
Authors: Andrew Howes, Richard L. Lewis
Journal: Behavioral and Brain Sciences (2018)

Abstract We argue that a radically increased emphasis on (bounded) optimality can contribute to cognitive science by supporting prediction. Bounded optimality (computational rationality), an idea that borrowed from artificial intelligence, supports a priori behavioral prediction from constrained generative models of cognition. Bounded optimality thereby addresses serious failings with the logic and testing of descriptive models of perception and action.
Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors.
Authors: Neil Howard Segal, Zev A. Wainberg, Michael J. Overman, Paolo Antonio Ascierto, Hendrik-Tobias Arkenau, Marcus O. Butler, Joseph Paul Eder, Ulrich Keilholz, Dong-Wan Kim, David Cunningham, Samir N. Khleif, Ludovic Doucet, Jong-Seok Lee, John J. Nemunaitis, Ulka N. Vaishampayan, Jared Weiss, Chen Gao, Shaad Essa Abdullah, Antoine Hollebecque
Journal: Journal of Clinical Oncology (2019)

670 Background: MSI-H tumors have shown to be responsive to PD-1 inhibitor therapy. We evaluated the anti-PD-L1 mAb durvalumab in patients with MSI-H tumors, in two ongoing studies: a phase 1/2, multicenter, open-label study in patients with advanced solid tumors, and a phase 2 single-center study in patients with advanced colorectal cancer (CRC). Methods: Patients with MSI-H tumors (determined locally by immunohistochemistry or sequencing) received durvalumab 10 mg/kg IV every 2 weeks for 12 months or until confirmed progressive disease, whichever was first. Objectives were to evaluate safety and antitumor activity (per investigator-assessed RECIST v1.1). Results: As of Oct 16, 2017, 62 MSI-H patients (97% with prior anti-cancer therapy) received treatment in the multicenter study; median duration of follow-up was 29 months. Treatment-related adverse events (TRAEs) occurred in 37 patients (60%), most commonly diarrhea (15%), asthenia (11%), fatigue (11%), nausea (10%), and hypothyroidism (10%). Grade 3/4 TRAEs occurred in 2 patients (3%). There were no deaths or treatment discontinuations due to TRAEs. Objective response rates (ORR) were 23% for the total population and 22% for patients with CRC; 9 of 14 responders were ongoing at data cutoff. As of Sep 13, 2018, 11 patients with MSI-H CRC were treated in the single-center study; median duration of follow-up was 30 months. One patient discontinued treatment due to treatment-related aseptic meningitis (resolved with steroids); response rate and survival were similar to the multicenter study (Table). Conclusions: Durvalumab had a tolerable safety profile, and showed promising antitumor activity and overall survival in patients with MSI-H tumors. Clinical trial information: NCT01693562 and NCT02227667. [Table: see text]
Early season estimate of influenza vaccination effectiveness against influenza hospitalisation in children, Hong Kong, winter influenza season 2018/19
Authors: Susan S Chiu, Mike YW Kwan, Shuo Feng, Eunice LY Chan, Huiying Chua, Joshua SC Wong, JS Malik Peiris, Benjamin J Cowling
Journal: Eurosurveillance (2019)

The winter 2018/19 influenza season in Hong Kong has been predominated by influenza A(H1N1)pdm09 as at January 2019. We enrolled 2,016 children in three public hospitals in Hong Kong between 2 September 2018 and 11 January 2019. Using the test-negative approach, we estimated high early season effectiveness of inactivated influenza vaccine against influenza A or B of 90% (95% confidence interval (CI): 80–95%) and 92% (95% CI: 82–96%) against influenza A(H1N1)pdm09.
Abstract 14097: Prediction of Heart Failure Symptoms at 12 Months From Baseline Factors in Patients With Heart Failure
Authors: Seongkum Heo, Debra K Moser, Terry A Lennie, Mary Fischer, Mary N Walsh, Songthip Ounpraseuth
Journal: Circulation (2017)

Introduction: More than 80% of patients with heart failure (HF) have been prescribed HF medications, but approximately 90% still experience HF symptoms, which have been associated with poor health-...
Using T Cell Receptor Repertoires to Understand the Principles of Adaptive Immune Recognition
Authors: Philip Bradley, Paul G. Thomas
Journal: Annual Review of Immunology (2019)

Adaptive immune recognition is mediated by antigen receptors on B and T cells generated by somatic recombination during lineage development. The high level of diversity resulting from this process posed technical limitations that previously limited the comprehensive analysis of adaptive immune recognition. Advances over the last ten years have produced data and approaches allowing insights into how T cells develop, evolutionary signatures of recombination and selection, and the features of T cell receptors that mediate epitope-specific binding and T cell activation. The size and complexity of these data have necessitated the generation of novel computational and analytical approaches, which are transforming how T cell immunology is conducted. Here we review the development and application of novel biological, theoretical, and computational methods for understanding T cell recognition and discuss the potential for improved models of receptor:antigen interactions.
Efficacy of liposomal-irinotecan (nal-IRI) plus 5-fluorouracil/folinic acid (5-FU/LV) versus oxaliplatin plus fluoropyrimidines in previous gemcitabine treated pancreatic adenocarcinoma (PAC) patients (pts).
Authors: Markus Kieler, Matthias Unseld, Daniela Bianconi, Werner Scheithauer, Gerald W. Prager
Journal: Journal of Clinical Oncology (2019)

383 Background: The chemotherapy regimens nal-IRI plus 5-FU/LV as well as oxaliplatin plus fluoropyrimidines are used after previous gemcitabine based chemotherapy in the 2 nd line treatment of metastatic PAC. We aimed to compare the clinical efficacy of these two treatment options. Methods: In this single institutional retrospective cohort analysis all pts with advanced PAC that were treated between 01/2012-08/2018 with nal-IRI plus 5-FU/LV or oxaliplatin plus fluoropyrimidines after previous 1 st line gemcitabine based chemotherapy were analysed for clinical parameters, median progression free survival (mPFS) and overall survival (mOS). Survival analyses were performed by Kaplan-Meier method. Results: Characteristics of pts were well matched (Table). mPFS in pts (n=30) that received nal-IRI plus 5-FU/LV in the 2 nd line treatment after gemcitabine based chemotherapy was 4.49 months while treatment with oxaliplatin plus fluoropyrimidines (n=31) resulted in a mPFS of 3.44 months (p=0.007, HR 0.47, 95% CI 0.27-0.81). Furthermore, pts with a CA 19-9 level &gt;1000 kU/l at the beginning of 2 nd line treatment had a significantly improved mPFS and mOS, when treated with nal-IRI plus 5-FU/LV compared to oxaliplatin plus fluoropyrimidines (mPFS 4.94 months versus 3.44 months, p=0.0186, HR 0.42, 95% CI 0.18-0.98; mOS 9.31 months versus 6.16 months, p=0.0386, HR 0.43, 95% CI 0.18-1.02). Conclusions: The efficacy of nal-IRI plus 5-FU/LV in our study is encouraging and outperforms oxaliplatin-based chemotherapy in the 2 nd line treatment setting for PAC pts pretreated with gemcitabine. Prospective randomized trials are urged to validate our observation. [Table: see text]